Copyright
©The Author(s) 2019.
World J Hepatol. Jun 27, 2019; 11(6): 542-552
Published online Jun 27, 2019. doi: 10.4254/wjh.v11.i6.542
Published online Jun 27, 2019. doi: 10.4254/wjh.v11.i6.542
Variable | Hazard ratio (95%CI) | P-value |
Tumour number | ||
Solitary | 1 | |
Multiple | 1.456 (1.236, 1.750) | <0.01 |
Log10 tumour size (cm) | 3.517 (2.678, 4.567) | <0.001 |
Baseline log10 AFP | 1.302 (1.208, 1.411) | <0.001 |
Baseline albumin | 0.993 (0.966, 0.998) | 0.031 |
Baseline log10 bilirubin | 1.581 (1.139, 2.194) | <0.001 |
Vascular invasion | ||
No | 1 | |
Yes | 1.612 (1.251, 2.045) | 0.001 |
Aetiology | ||
Hepatitis C virus | 1 | |
hepatitis B virus | 1.260 (1.020, 1.407) | <0.05 |
Others | 0.914 (0.887, 0.991) | 0.043 |
- Citation: Elshaarawy O, Alkhatib A, Elhelbawy M, Gomaa A, Allam N, Alsebaey A, Rewisha E, Waked I. Validation of modified albumin-bilirubin-TNM score as a prognostic model to evaluate patients with hepatocellular carcinoma. World J Hepatol 2019; 11(6): 542-552
- URL: https://www.wjgnet.com/1948-5182/full/v11/i6/542.htm
- DOI: https://dx.doi.org/10.4254/wjh.v11.i6.542